Joel I Reisman
Overview
Explore the profile of Joel I Reisman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jasuja G, Reisman J, Jefferson C, Hall R, Van Cleve R, Bishop T, et al.
Med Care
. 2025 Mar;
PMID: 40068137
Background: Pride in All Who Served (PRIDE) is an intervention in the Veterans Health Administration (VHA) focused on enhancing Lesbian, Gay, Bisexual, Transgender, and Queer (LGBTQ+) veterans' access to affirmative...
2.
Leon C, Sung M, Reisman J, Liu W, Kerns R, Gordon K, et al.
Clin J Pain
. 2024 Dec;
41(2).
PMID: 39682036
Objective: Neurocognitive symptoms (NCSs) may be early indicators of opioid-related harm. We aimed to evaluate the incidence and potential attribution of opioid-related NCS among patients on long-term opioid therapy (LOT)...
3.
Sung M, Leon C, Reisman J, Gordon K, Kerns R, Li W, et al.
Subst Use Addctn J
. 2024 Nov;
46(2):369-376.
PMID: 39569566
Background: Populations disproportionately impacted by the opioid epidemic are less likely to receive medications for opioid use disorder (MOUD; OUD). The COVID-19 pandemic exacerbated these disparities. We performed an ecological...
4.
Kwon S, Wang X, Liu W, Druhl E, Sung M, Reisman J, et al.
Proc Conf
. 2024 Sep;
2024:4338-4359.
PMID: 39224833
Opioid related aberrant behaviors (ORABs) present novel risk factors for opioid overdose. This paper introduces a novel biomedical natural language processing benchmark dataset named ODD, for ORAB Detection Dataset. ODD...
5.
Jasuja G, Wolfe H, Reisman J, Vimalananda V, Rao S, Blosnich J, et al.
Front Endocrinol (Lausanne)
. 2024 Jul;
15:1448887.
PMID: 39040672
[This corrects the article DOI: 10.3389/fendo.2024.1086158.].
6.
Jasuja G, Wolfe H, Reisman J, Vimalananda V, Rao S, Blosnich J, et al.
Front Endocrinol (Lausanne)
. 2024 May;
15:1086158.
PMID: 38800485
Background: Gender-affirming hormone therapy (GAHT) is a common medical intervention sought by transgender and gender diverse (TGD) individuals. Initiating GAHT in accordance with clinical guideline recommendations ensures delivery of high-quality...
7.
Wolfe H, Vimalananda V, Wong D, Reisman J, Rao S, Shipherd J, et al.
Transgend Health
. 2024 May;
9(2):151-161.
PMID: 38694620
Purpose: This study aimed to examine patient characteristics associated with receipt of gender-affirming hormone therapy in the Veterans Health Administration (VHA). Methods: This cross-sectional study included a national cohort of...
8.
Jasuja G, Reisman J, Miller D, Ansara E, Chiulli D, Moore T, et al.
Am J Health Syst Pharm
. 2024 Mar;
81(11):e289-e295.
PMID: 38468398
Purpose: The complexity of patients with mental healthcare needs cared for by clinical pharmacists is not well delineated. We evaluated the complexity of patients with schizophrenia, bipolar disorder, and major...
9.
Miller D, Reisman J, McDannold S, Kleinberg F, Gillespie C, Zogas A, et al.
Am J Health Syst Pharm
. 2023 Aug;
80(22):1637-1649.
PMID: 37566141
Purpose: To evaluate whether clinical pharmacist practitioners (CPPs) are being utilized to care for patients with complex medication regimens and multiple chronic illnesses, we compared the clinical complexity of diabetes...
10.
Borzecki A, Conti J, Reisman J, Vimalananda V, Nagy M, Paluri R, et al.
J Endocr Soc
. 2023 Jun;
7(7):bvad075.
PMID: 37362384
Context: Accurate measures to assess appropriateness of testosterone prescribing are needed to improve prescribing practices. Objective: This work aimed to develop and validate quality measures around the initiation and monitoring...